Sensorion

147 articles about Sensorion

• Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

  6/7/2022

  Sensorion announces, that the initiation of a Proof of Concept clinical trial of SENS-401 in patients scheduled for cochlear implantation has been approved by regulatory authorities in France.

• Sensorion to Attend the American Society of Gene & Cell Therapy (ASGCT) and Gene Therapy Analytical Development Conferences in May 2022

  5/12/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of Sensorion’s management in two scientific conferences being held in May 2022.

• Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 31, 2022

  5/10/2022

  Sensorion announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Tuesday, May 31, 2022, at 2 pm CET in the premises of the hotel L’Arcade, located at 9 rue de l’Arcade, 75008, Paris.

• Sensorion Full-Year 2021 Financial Results and Business Highlights

  4/28/2022

  Sensorion announces its full-year 2021 financial results and provides an update on its business activities and outlook for 2022.

• Sensorion Announces the Publication of Its 2021 Annual Financial Report

  4/28/2022

  Sensorion announces that its annual financial report for the year ending December 31, 2021, is available to the public and filed with the French financial market authority.

• Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022

  4/21/2022

  Sensorion is pleased to announce the participation of CEO Nawal Ouzren in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, being held virtually on April 25-26, 2022.

• Sensorion to Attend the Kempen Life Sciences, Cell & Gene Meeting on the Mediterranean Conferences in April 2022

  4/12/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that CEO Nawal Ouzren will attend in person two investor meetings in April 2022.

• Sensorion Will Present at The H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on March 30th, 2022

  3/25/2022

  Sensorion is pleased to announce the participation of Sensorion’s CEO, Nawal Ouzren, in the H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference, an investor meeting being held on March 30th, 2022.

• Sensorion Provides Preliminary Documents for the Extraordinary General Meeting of April 14th, 2022

  3/24/2022

  Sensorion announces that the Company’s shareholders are invited to participate in the Extraordinary General Meeting, to be held on Thursday, April 14th, 2022, at 2 pm CET in the premises of the hotel L’Arcade, located at 9 rue de l’Arcade, 75008, Paris.

• Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona

  3/18/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation in person of Sensorion’s management in the Bioprocessing Summit Europe, held in person and virtually on March 22-24, 2022 in Barcelona, Spain.

• Sensorion Update on SENS-401

  3/17/2022

  Sensorion provides an update following supplementary analysis of the 115-patient Phase 2 AUDIBLE-S study of SENS-401 for the treatment of sudden sensorineural hearing loss.

• Sensorion to Present Three Posters on SENS-401 in Cisplatin Ototoxicity Models at the Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting

  2/3/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce it will present three posters on SENS-401 in Cisplatin Ototoxicity models at the 2022 Association for Research in Otolaryngology MidWinter Meeting.

• Sensorion to Present New Data on OTOF Gene Therapy at the Association for Research in Otolaryngology ARO 45th Annual MidWinter Meeting

  2/1/2022

  Sensorion is pleased to announce its participation at the 2022 Association for Research in Otolaryngology MidWinter Meeting, where it will take part in a workshop and present a poster on gene therapy.

• 

  Sensorion Hears Disappointing Results from Study of Key Asset

  1/18/2022

  The company will continue to analyze data regarding the secondary endpoints.

• Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss

  1/17/2022

  Sensorion reports results from the 115-patient Phase 2 AUDIBLE-S study of SENS-401, for the treatment of sudden sensorineural hearing loss.

• Sensorion appoints Aniz Girach as Independent Board Member

  1/4/2022

  Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that Aniz Girach, MD, is joining the Board of directors as an independent Board member.

• Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director

  12/20/2021

  Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director.

• Sensorion to present in person at “Jefferies London Healthcare Conference”

  11/9/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that Nawal Ouzren, CEO of Sensorion, will participate physically in one investor conference in London.

• Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022

  10/27/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces 115 patients have been enrolled for treatment in the company’s AUDIBLE-S study of the company’s first-in-class small molecule drug SENS-401 in patients with sudden sensorineural hearing loss.

• Sensorion to Present at “Jefferies Gene Therapy / Editing Summit”

  10/22/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team at an investor conference.